Wei Z.-L.,Renovis Inc. |
Nguyen M.T.,Renovis Inc. |
O'Mahony D.J.R.,Renovis Inc. |
Acevedo A.,Renovis Inc. |
And 13 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2015
Abstract Antagonists of the TRPV4 receptor were identified using a focused screen, followed by a limited optimization program. The leading compounds obtained from this exercise, RN-1665 23 and RN-9893 26, showed moderate oral bioavailability when dosed to rats. The lead molecule, RN-9893 26, inhibited human, rat and murine variants of TRPV4, and showed excellent selectivity over related TRP receptors, such as TRPV1, TRPV3 and TRPM8. The overall profile for RN-9893 may permit its use as a proof-of-concept probe for in vivo applications. © 2015 Elsevier Ltd.
Renovis Inc. | Date: 2014-07-24
A surgical implant device, comprising: a body portion; and one or more surfaces comprising a plurality of protruding structures; wherein the body portion and the one or more surfaces comprising the plurality of protruding structures are integrally formed. The one or more surfaces comprising the plurality of protruding structures are formed by an additive manufacturing process. The plurality of protruding structures comprise a plurality of needles. Optionally, the surgical implant device comprises one of an anterior lumbar interbody fusion cage, a posterior lumbar interbody fusion cage, a transforaminal lumbar interbody fusion cage, an oblique lumbar interbody fusion cage, a cervical cage, and a bone screw.